Sunitinib Malate 12.5mg Capsules are an oral multi-targeted tyrosine kinase inhibitor used for the targeted treatment of various advanced malignancies.
It acts by inhibiting tumor angiogenesis and cell proliferation, and is indicated for the treatment of certain advanced renal cell carcinoma, gastrointestinal stromal tumors, pancreatic neuroendocrine tumors, and other malignant tumors.
Each capsule contains Sunitinib Malate equivalent to 12.5mg of Sunitinib as the active ingredient. Manufactured under strict GMP standards and compliant with BP, USP, ICH requirements.
Key Features:
Potent multi-targeted anti-tumor activity
Inhibits tumor angiogenesis and proliferation
Stable quality and consistent bioavailability
GMP certified production
Complete registration documents available
Wholesale and bulk supply supported
Storage:
Store in a cool, dry place, protected from light and moisture.
